AIBOTICS' Losses Widen Amidst Minimal Revenue, Going Concern Doubt

Ticker: AIBT · Form: 10-Q · Filed: Nov 19, 2025 · CIK: 1763329

Sentiment: bearish

Topics: Going Concern, Net Loss, Working Capital Deficit, Micro-cap, Pre-revenue, Dilution, Financial Risk

TL;DR

**AIBT is burning cash with no real revenue, making it a highly speculative bet with significant going concern risk.**

AI Summary

AIBOTICS, INC. (AIBT) reported a net loss of $1,607,467 for the nine months ended September 30, 2025, an increase from a net loss of $1,356,761 in the same period of 2024. The company generated minimal revenue of $2,183 for the nine months ended September 30, 2025, compared to zero revenue in the prior year. Operating expenses rose to $1,372,591 for the nine months ended September 30, 2025, up from $1,137,539 in 2024, primarily due to increased general and administrative costs. AIBT's cash position improved to $230,470 as of September 30, 2025, from $185,097 at December 31, 2024, largely driven by financing activities, including $250,000 from convertible notes and $167,009 from common stock issuance. The company faces a significant working capital deficit of $4,661,176 as of September 30, 2025, with total current assets of $241,396 against current liabilities of $4,902,572. Intangible assets, net, decreased to $775,547 from $1,271,898, reflecting amortization expense of $496,351. The filing explicitly states a 'going concern' doubt due to sustained operating losses and negative cash flows.

Why It Matters

AIBOTICS' persistent net losses and substantial working capital deficit raise serious red flags for investors, indicating a high risk of financial instability and potential dilution. The company's inability to generate meaningful revenue, despite increased operating expenses, suggests a struggle to commercialize its offerings, putting pressure on its ability to compete in the AI and therapeutics space. Employees face uncertainty regarding job security, while customers might question the long-term viability of AIBT's products or services. The broader market will view AIBT as a speculative micro-cap with significant operational challenges, potentially impacting investor sentiment for similar early-stage, pre-revenue companies.

Risk Assessment

Risk Level: high — AIBOTICS reported a net loss of $1,607,467 for the nine months ended September 30, 2025, and a working capital deficit of $4,661,176, with current liabilities of $4,902,572 far exceeding current assets of $241,396. The filing explicitly states 'These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year.'

Analyst Insight

Investors should exercise extreme caution and avoid AIBT stock given the severe going concern risk, persistent losses, and minimal revenue. Current shareholders should consider divesting, as further dilution or financial distress appears highly probable without a significant, immediate capital infusion or a drastic change in operational profitability.

Financial Highlights

debt To Equity
N/A
revenue
$2,183
operating Margin
N/A
total Assets
$1,016,943
total Debt
$4,902,572
net Income
-$1,607,467
eps
-$0.02
gross Margin
100.0%
cash Position
$230,470
revenue Growth
N/A

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$2,183N/A

Key Numbers

Key Players & Entities

FAQ

What is AIBOTICS, INC.'s net loss for the nine months ended September 30, 2025?

AIBOTICS, INC. reported a net loss of $1,607,467 for the nine months ended September 30, 2025, which is an increase from the $1,356,761 net loss reported for the same period in 2024.

Does AIBOTICS, INC. have a going concern issue?

Yes, the filing explicitly states that AIBOTICS, INC. has a going concern issue. This is due to incurring a net loss of $1,607,467, negative cash flows from operations of $371,636, and a working capital deficit of $4,661,176 as of September 30, 2025.

What was AIBOTICS, INC.'s revenue for the nine months ended September 30, 2025?

AIBOTICS, INC. generated minimal revenue of $2,183 for the nine months ended September 30, 2025. This is a slight increase compared to no revenue reported for the same period in 2024.

How much cash did AIBOTICS, INC. have as of September 30, 2025?

As of September 30, 2025, AIBOTICS, INC. had $230,470 in cash. This represents an increase from $185,097 at December 31, 2024.

What is the working capital deficit for AIBOTICS, INC. as of September 30, 2025?

AIBOTICS, INC. reported a significant working capital deficit of $4,661,176 as of September 30, 2025. This is calculated from total current assets of $241,396 and total current liabilities of $4,902,572.

How many shares of common stock were outstanding for AIBOTICS, INC. as of November 19, 2025?

As of November 19, 2025, AIBOTICS, INC. had 440,612,707 shares of common stock outstanding. This indicates substantial share issuance and potential dilution.

What were the total operating expenses for AIBOTICS, INC. for the nine months ended September 30, 2025?

Total operating expenses for AIBOTICS, INC. amounted to $1,372,591 for the nine months ended September 30, 2025. This is an increase from $1,137,539 for the same period in 2024.

What is AIBOTICS, INC.'s strategy to address its liquidity problems?

AIBOTICS, INC.'s management is actively pursuing additional equity financing through discussions with investment bankers and private investors to improve the company's liquidity. However, there is no assurance that these efforts will be successful.

What was the amortization expense for AIBOTICS, INC. for the nine months ended September 30, 2025?

AIBOTICS, INC. recorded an amortization expense of $496,351 for the nine months ended September 30, 2025. This contributed to the decrease in intangible assets, net, from $1,271,898 to $775,547.

What was the net loss per share for AIBOTICS, INC. for the nine months ended September 30, 2025?

The net loss per share for AIBOTICS, INC. was $0.02 for the nine months ended September 30, 2025. This is an improvement from $0.11 per share in the prior year, primarily due to a significantly higher average number of common shares outstanding.

Risk Factors

Industry Context

AIBOTICS, INC. operates in a sector that often requires significant R&D investment and faces long development cycles. The competitive landscape can be intense, with established players and emerging startups vying for market share and funding. Industry trends often involve rapid technological advancements and evolving regulatory frameworks, demanding continuous innovation and adaptation.

Regulatory Implications

As a company with a 'going concern' warning, AIBT faces heightened scrutiny from regulatory bodies like the SEC. Failure to address its financial instability could lead to delisting from exchanges or further regulatory actions. Compliance with financial reporting standards is critical to maintain any investor confidence.

What Investors Should Do

  1. Review the 'Commitments and contingencies' note (Note 9) for any undisclosed liabilities or obligations that could exacerbate the going concern risk.
  2. Analyze the terms and maturity dates of convertible notes and related party debt to understand immediate cash flow pressures and potential dilution events.
  3. Seek clarification on the strategy to generate revenue and achieve profitability, given the minimal revenue and increasing losses reported.
  4. Evaluate the feasibility of any proposed financing or restructuring plans that management might present to address the going concern issue.
  5. Consider the significant dilution risk associated with the large number of authorized and issued shares, especially if further financing is required.

Key Dates

Glossary

Going Concern
An accounting principle that assumes a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The filing explicitly states a 'going concern' doubt, indicating significant financial distress and potential inability to meet obligations.)
Working Capital Deficit
Occurs when a company's current liabilities exceed its current assets, indicating a potential inability to meet short-term obligations. (AIBT has a substantial deficit of $4,661,176 as of September 30, 2025, highlighting severe liquidity issues.)
Intangible Assets, Net
Assets that lack physical substance but have value, such as patents or goodwill, net of accumulated amortization. (Decreased by $496,351 due to amortization, impacting the company's asset base.)
Amortization Expense
The systematic allocation of the cost of an intangible asset over its useful life. (Contributed to the reduction of intangible assets by $496,351 for the nine months ended September 30, 2025.)
Convertible Note Payable
A debt instrument that can be converted into a predetermined amount of equity in the issuing company. (AIBT raised $250,000 from convertible notes, contributing to its cash balance but also representing future potential dilution.)
Accumulated Deficit
The total net losses of a company since its inception that have not been offset by net income. (Stands at a substantial $(12,416,723)$ as of September 30, 2025, reflecting persistent unprofitability.)
Shares to be Issued
Represents shares that have been committed to be issued but have not yet been formally delivered. (A significant liability of $1,995,600 as of September 30, 2025, indicating future equity dilution or obligations.)
Mezzanine Equity
A hybrid form of financing that blends debt and equity features, often subordinate to senior debt. (The Series B Preferred stock is listed under this category, though it has a liquidation preference of $0.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, AIBOTICS, INC. has seen its net loss widen from $1,356,761 to $1,607,467, and its operating expenses increase from $1,137,539 to $1,372,591. While revenue has emerged from zero to $2,183, it remains negligible. The company's working capital deficit has dramatically worsened, and the explicit 'going concern' doubt is a new and critical risk factor highlighted in this filing.

Filing Stats: 4,552 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2025-11-19 14:29:55

Key Financial Figures

Filing Documents

—Financial Information

Part I—Financial Information 1

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 202 4 4 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Mezzanine Equity and Stockholders' Deficit for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 21 4

Controls and Procedures

Controls and Procedures 21

—Other Information

Part II—Other Information 6 Exhibits 22

–FINANCIAL INFORMATION

PART I–FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS AIBOTICS THERAPIES, INC CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2025 2024 (unaudited) ASSETS CURRENT ASSETS: Cash $ 230,470 $ 185,097 Other receivable 10,926 - Total Current Assets 241,396 185,097 NON-CURRENT ASSETS: Intangible assets, net 775,547 1,271,898 TOTAL ASSETS $ 1,016,943 $ 1,456,995 LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Accounts payable and accrued expenses $ 481,845 $ 283,341 Accrued interest 179,710 399,822 Accrued expenses – related party 765,000 864,000 Convertible note payable, net of debt discount 1,315,417 1,100,000 Notes payable – related party 165,000 165,000 Shares to be issued 1,995,600 2,039,600 TOTAL LIABILITIES 4,902,572 4,851,763 Commitments and contingencies (Note 9 – Commitments and Contingencies) - - MEZZANINE EQUITY Series B Preferred stock, $ 0.001 par value; 1,500,000 shares authorized at September 30, 2025 and December 31, 2024; 200 shares issued and outstanding as of September 30, 2025 and December 31, 2024; liquidation preference of $ 0 as of September 30, 2025 and December 31, 2024 200 200 STOCKHOLDERS' DEFICIT Preferred stock, 5,000,000 shares authorized: Series A Preferred Stock, $ 0.001 par value, 0 shares authorized at September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively - - Common stock, $ 0.001 par value, 467,000,000 shares authorized; 318,890,559 and 39,990,903 , shares issued and outstanding, at September 30, 2025 and December 31, 2024, respectively. 318,890 39,991 Additional paid in capital 8,212,004 7,374,297 Accumulated deficit ( 12,416,723 ) ( 10,809,256 ) TOTAL STOCKHOLDERS' DEFICIT ( 3,885,629 ) ( 3,394,768 ) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT $ 1,016,943 $ 1,456,995 The accompanying notes a

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing